You are currently viewing a new version of our website. To view the old version click .
by
  • Masutaka Furue1,*,† and
  • Mihoko Furue2

Reviewer 1: Anonymous Reviewer 2: Anonymous Reviewer 3: Anonymous

Round 1

Reviewer 1 Report

The article does not add anything new compared to the existing literature: 90 papers on IL 31 and itching of which 30 reviews are already viewable on pubmed. Overall the article is well written and well structured.

 

Author Response

Reply to the Reviewer 1

 

The article does not add anything new compared to the existing literature: 90 papers on IL 31 and itching of which 30 reviews are already viewable on pubmed. Overall the article is well written and well structured.

 

→ Thank you very much for your encouraging and helpful comments. As you mentioned, this is a completely review article but we did our best to describe the updated information. We hope your kind understanding.

Reviewer 2 Report

I read with great interested this review article by Furue and cols. I only have a few minor comments. 

  1. Abstract, line 7. I recommend to avoid mention about pain. We know now that inflammation is related to itch and not necessary pain.
  2. Introduction, line 21. The use of the term "short-term pruritus" is not well know, and I believe the use "Acute pruritus" would be more appropriate.
  3. Introduction, line 25. What the authors mean with "miscellaneous eczema"? Please clarified 
  4. Section 2. IL-31 and its signaling. Line 41. IL-31 belongs to the IL-6 or it is related? please clarify 
  5. Figure 1 Substance P is not related to its receptor NK1R, the authors are mentioning this as part of the transmission of itch, or missed the receptor? Please clarify    

 

Author Response

Reply to the Reviewer 2

I read with great interested this review article by Furue and cols. I only have a few minor comments. 

→ Thank you very much for your encouraging comments.

  1. Abstract, line 7. I recommend to avoid mention about pain. We know now that inflammation is related to itch and not necessary pain.

→ Thank you very much for your helpful comment. We agree with you. We delete this sentence in the revised article.

 

  1. Introduction, line 21. The use of the term "short-term pruritus" is not well known, and I believe the use "Acute pruritus" would be more appropriate.

→ Thank you very much for your helpful comment. We amended this term to “Acute pruritus”. Thanks again.

  1. Introduction, line 25. What the authors mean with "miscellaneous eczema"? Please clarified 

→ Thank you very much for your helpful comment. We amended this term to “eczema”. Thanks again.

 

  1. Section 2. IL-31 and its signaling. Line 41. IL-31 belongs to the IL-6 or it is related? please clarify 

→ Thank you very much for your comment. We amended this part to “IL-31 belongs to the “gp130/IL-6 cytokine family”.

 

  1. Figure 1 Substance P is not related to its receptor NK1R, the authors are mentioning this as part of the transmission of itch, or missed the receptor? Please clarify    

→ Thank you very much for your comment. We understand your question. However, to the best of our knowledge, previous studies clarified that IL-31R+ neurons probably co-express substance P. But it is not still clear whether substance P can activate IL-31R+ neurons or mediated IL-31-induced pruritus.   

We hope the revised article is now suitable for publication in JCM.

Reviewer 3 Report

This is a well-written comprehensive review article giving an overview of the role of the IL-31 pathway in chronic itch. I have only one minor suggestion for the authors: authors could consider adding 1 figure summarizing the IL-31 pathway and signaling (section 2 of the manuscript) and 1 table providing an overview of the performed RCTs with antibodides targeting IL-31 including indication and main results.

Author Response

Reply to the Reviewer 3

This is a well-written comprehensive review article giving an overview of the role of the IL-31 pathway in chronic itch. I have only one minor suggestion for the authors: authors could consider adding 1 figure summarizing the IL-31 pathway and signaling (section 2 of the manuscript) and 1 table providing an overview of the performed RCTs with antibodides targeting IL-31 including indication and main results.

→ Thank you very much for your encouraging and helpful comments. According to your comment, we added Figure 1 and Table 2 in the revised article.

 

We hope the revised article is now suitable for publication in JCM.